Northwest Biotherapeutics Announces $5 Million Financing

On August 21, 2020 Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported that the Company has completed a non-dilutive debt financing for net proceeds of another $5 million (Press release, Northwest Biotherapeutics, AUG 21, 2020, View Source [SID1234563936]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company anticipates that this financing will help further build the Company’s momentum by providing resources for expansion of production capacity and for ramp up of certain readiness activities as the Company approaches the readout of topline data from its Phase III trial of DCVax-L for Glioblastoma.

The Company entered into this 21-month Note (the "Loan") on August 17, 2020 for $5,505,000 at an 8% annualized interest rate, with no payments due for the first 7 months. Prepayment of the Loan can be made at any time with a 15% prepayment penalty. If the Loan remains outstanding past month 8, it will be amortized through month 21 with monthly payments of 110% of 14 equal monthly principal payments. The note also includes a $500,000 original issue discount. The lender is Iliad Research and Trading, LP.

Health Kick Podcast: Chemo’s diminishing role, the ‘personalised’ approach to cancer treatment and PTX’s CAR-T innovations

On August 21, 2020 Prescient reported that it is focused on developing novel, personalised therapies against a range of cancers (Press release, Prescient Therapeutics, AUG 21, 2020, View Source;utm_medium=rss&utm_campaign=health-kick-podcast-chemos-diminishing-role-the-personalised-approach-to-cancer-treatment-and-ptxs-car-t-innovations [SID1234567639]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.

Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, and spanning a range of different cancers.

The company made headlines earlier this month with news of its partnership with global cancer heavyweight Peter MacCallum Cancer Centre to develop new treatments.

Invitation to presentation of BioInvent’s second quarter report 2020 on August 27, 2020

On August 21, 2020 BioInvent International AB (OMXS: BINV) reported that it will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed by an audiocast with teleconference at 5.30 p.m. CEST, hosted by Martin Welschof, CEO and members of the management team (Press release, BioInvent, AUG 21, 2020, View Source [SID1234563938]). The presentation will be held in English.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate, please call any of the following phone numbers from:

Webcast: View Source

Kintara Therapeutics Announces Additional $2.4 Million Private Placement Priced At-The-Market

On August 21, 2020 Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) reported that it has entered into definitive agreements with investors providing for the sale and issuance of up to 2,435 shares of its Series C Convertible Preferred Stock (the "Preferred Stock") at a purchase price of $1,000 per share in a private placement offering priced at-the-market under the rules of the Nasdaq Stock Market (Press release, Kintara Therapeutics, AUG 21, 2020, View Source [SID1234563939]). The Preferred Stock is convertible into shares of Kintara common stock at a conversion price of $1.214 per share. The offering is expected to result in gross proceeds to Kintara of up to approximately $2.4 million which is in addition to the $19.6 million previously announced. The Preferred Stock accrues dividends as previously announced.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The private placement is expected to close on or about August 24, 2020, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme (GBM), the 15-patient REM-001 confirmatory lead-in study intended to continue seamlessly into a full Phase 3 pivotal study for Cutaneous Metastatic Breast Cancer (CMBC), and for working capital. Also, as previously disclosed, the GBM trial will be executed through the Company’s partnership with Global Coalition for Adaptive Research (GCAR) through the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study, an adaptive clinical trial platform in GBM.

The shares of Preferred Stock described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "Act"), and, along with the common shares issuable upon their exercise or payable as dividends pursuant to the Preferred Stock, have not been registered under the Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners

On August 20, 2020 AbCellera reported the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics) (Press release, AbCellera, AUG 20, 2020, View Source [SID1234622736]). OrthoMab is a clinically validated platform that uses the most advanced computational and experimental protein engineering methods to create IgG-like bispecific antibodies from any two antibody sequences . By integrating OrthoMab into its existing technology stack, AbCellera provides the industry with a rapid and complete solution for generating tailored, stable and developable bispecific antibodies that meet the needs of the growing $140B biologics market.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs. Dr. Tim Jacobs, who led multiple bispecific antibody programs as CTO of Dualogics, joined AbCellera’s team in early August. Dr. Jacobs brings 10 years of protein engineering experience and has pioneered numerous computational and experimental strategies to design, modify, and enhance protein-based therapies.

"Bispecifics have opened new vistas for antibody therapeutics and are the fastest growing format in clinical development. Despite this early success, the technological barriers for successful development of bispecifics, including challenges in discovery, pair selection, protein engineering and manufacturing, are keeping many firms out," said Carl Hansen, Ph.D., CEO of AbCellera. "By welcoming Tim to our team and OrthoMab into our stack, we have consolidated the talent and technologies needed to address these challenges. Through our partnerships, we’ll democratize access to leading bispecific technology across the industry, connecting science with technology to bring new therapies to the clinic."

The addition of OrthoMab to AbCellera’s antibody discovery technology creates a unified bispecific platform that optimizes every step of the process, including:

Sourcing diverse antibodies from any animal, including fully human monoclonal antibodies from humanized mice;
Searching, decoding, and analyzing antibodies to identify the best combinations for achieving the desired functions;
Engineering IgG-like bispecific antibodies that are tailored to maximize therapeutic effect while retaining optimal stability and developability profiles; and
Assessing immunogenicity with in silico screening tools.
"AbCellera’s deep technical expertise and industry-leading discovery pipeline uniquely positions it to make the most of the OrthoMab platform," said Tim Jacobs, Ph.D., Senior Research Scientist at AbCellera. "I am extremely excited to be joining the AbCellera team and look forward to bringing best-in-class bispecific and protein-engineering capabilities to our partners."